Carregant...

Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells

Doxorubicin (DOX) is the most common chemotherapeutic drug for treatment of breast cancer but intrinsic and acquired resistance frequently occurs and severe side effects occur at high doses. DOX might induce activation of NF-κB causing this resistance, in which case proteasome inhibitors could inhib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Clin Exp Pathol
Autors principals: Shi, Yonghua, Bieerkehazhi, Shayahati, Ma, Hong
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6958235/
https://ncbi.nlm.nih.gov/pubmed/31938346
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!